Zimmer Biomet — Feb 6, 2025 release

  Page 4 of 24   Financial Guidance The Company is providing the following full-year 2025 financial guidance: Projected Year Ending December 31, 2025 2025 Reported Revenue Change 1.0% - 3.5% Foreign Currency Exchange Impact (2.0)% - (1.5)% 2025 Constant Currency Revenue Change 3.0% - 5.0% Adjusted Diluted EPS (1) $8.15 - $8.35   (1) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.   Conference Call The Company will conduct its fourth quarter and full-year 2024 investor conference call today, February 6, 2025, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artifici